Erez Israeli: The main growth will come from investment in differentiated product and the specialty products and collaborations that we are working. So, we are planning to introduce a lot of innovation in India, and we are building it. In addition to that, we will continue to focus on the brands that we believe can contribute in short-term, but much more in the long-term. And we will continue also to invest in the capabilities to market within the most productive manner using all the relevant digital tools and the ability to maximize the return on the investment. We are going to see also in India continue divestiture of the brands that we are not planning to invest behind. If we believe that the returns that will come from those divestitures will be more than what we will get if we continue to market it.
So, in that respect, we are well within our strategy. And maybe the results here and there will fluctuate because of brands, but overall I’m very confident that will be top five as per the targets that we shared with you .
Damayanti Kerai: Sure. And in the portfolio, which you have done some time back, are the results in line with your initial expectation, or do you think you have further headroom to see better sales for some of the top brands?
Erez Israeli: The product sales, they’re not serving us very well. I’m very happy with these acquisitions there. It’s already exceeded expectations.
Damayanti Kerai: My last question is on Russia, besides a very strong quarter which you mentioned there were biosimilars, which contributed, so do we assumed it to be sustainable sales or this is driven by someone one-time pick up and we might see moderation from here on?
Erez Israeli: Russia will continue to be strong for us. Quarter wise, it will fluctuate. This quarter it’s a timing of the bits with the government on biosimilars for example. So, unlikely that we will see that in the other quarter. So, it will fluctuate, but overall we are going to see in the local currency growth and as related to the protection the ruble, I think we have very lucky for this year. We’re very good the protection on the ruble itself. So, we are — I am optimistic from both — from even with the scenarios that there will be a significant devaluation of the ruble.
Damayanti Kerai: That’s helpful. Thank you very much. I’ll get back in the queue.
Operator: Thank you. Next question is from the line of Surya Patra from Philip Capital. Please go ahead.
Surya Patra: Yes, thank you, sir. Thanks for the great set of numbers. Just on the REVLIMID side, if you could say something more on the kind of visibility in terms of — like — it seems that first two quarters — or in the last two quarters, whatever number that we would have generated, it seems that we have already achieved around 5% odd mid-single-digit kind of volume set in the product opportunity. So, considering that, is it fair to think that fourth quarter and first quarter possibly could be a relatively low number that we could see from REVLIMID?
Erez Israeli: I cannot share any numbers about that, so–
Surya Patra: Okay. But could you give some sense about let’s say, in terms of the volume set, whatever that is fixed for the first year, how different the volume share number would be for second year? Ballpark indicate–.
Erez Israeli: Again, it’s not because I would love to share, but I can’t. We have an agreement and I have to honor the agreement. So, please bear with me on that.
